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Background:  Differentiating  the  different  follicular  derived  lesions  from  each  other  can  be
challenging.  Although  immunohistochemistry  is generally  accepted  as  a  useful  ancillary
technique  in  the  diagnosis,  controversy  exists  regarding  the  best  marker  or  combination
of  markers  to distinguish  each  lesion  from  its mimics.  In this  study,  we aimed  at  evalu-
ating  multiple  markers  to compare  their  sensitivity  and  usefulness,  and to  ﬁnd  out  if a
combination  of  the  evaluated  markers  can  be  of  additional  value  in  discriminating  thyroid
lesions.
Methods:  The  study  included  two groups  of follicular  derived  thyroid  lesions.  Immunohis-
tochemical  evaluation  of  CD56,  HBME-1,  Gaectin-3  and  CK19  was  done  for  the  two  groups.
The sensitivity  and  the  speciﬁcity  for each  marker  and  their  combination  in  the  diagnosis
were  calculated.
Results:  Each  studied  marker  was  sensitive  and  speciﬁc  for certain  thyroid  lesion  but the
sensitivity and  the  speciﬁcity  were  increased  when  two  or more  markers  from  the  panel
were  used  together.
Conclusions:  Although  no  single  immunohistochemical  marker  by itself  is completely  sensi-
tive and  speciﬁc  for  follicular  thyroid  lesions,  the  combination  of  CD56,  HBME-1,  Gaectin-3
and  CK19  attains  high  sensitivity  and  speciﬁcity  in  differentiating  follicular  derived  thyroid
lesions.
© 2014  Saudi  Society  of  Microscopes.  Published  by  Elsevier  Ltd.  All  rights  reserved.. Introduction
Follicular derived thyroid disease refers to the pres-
nce of a benign or malignant solid nodule, a multinodular
land, Grave’s disease, or thyroiditis. The microscopic dis-
inction  by conventional histology between benign and
alignant lesions may  be difﬁcult [1,2]. Most of the
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213-879X/© 2014 Saudi Society of Microscopes. Published by Elsevier Ltd. All ridiscovered nodules are benign. More than 80% of the malig-
nancies present in palpable thyroid nodules are papillary
thyroid carcinoma (PTC) followed by follicular carcinoma
(FC) [3–5].
The  “gold standard” in diagnosis of thyroid nodules is
pathologic evaluation using routine hematoxylin and eosin
(H&E)  staining. However, morphologic overlap between
follicular lesions especially the follicular variant of papil-
lary  carcinoma (FVPC) is common which is characterized
by an almost exclusive follicular growth pattern and a
set  of nuclear features identical to those of the classic
type of PTC [6,7]. Diagnostic dilemma may  arise when an
encapsulated nodule with a follicular pattern of growth
exhibits clear nuclei with grooves and so distinguishing
ghts reserved.
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Table 1
The  distribution of the studied cases.
Studied cases
Normal (n = 10)
Lesions (n = 70) First group
(n  = 20)
Grave’s  disease
(n  = 4)
MNG (n = 5)
Hashimoto’s
thyroiditis (n = 4)
FA (n = 7)
Second  group
(n  = 50)
PTC  (n = 22)
FTC (n = 15)128 H.A. Alshenawy / Journal of Micros
follicular adenoma (FA) from encapsulated FVPTC becomes
difﬁcult. There are several other thyroid lesions that may
contain  papillary processes with nuclear features, which
pose  diagnostic difﬁculties with PTC [8]. Multinodular
goiter (MNG) with delicate papillary budding and focal
nuclear clearing may  be confused with PTC [9,10]. Also
a  new category emerged that was named Follicular Neo-
plasm/atypical cells of undetermined signiﬁcance (AUS).
This  category accounts for 10–25% of all cases and rep-
resents a therapeutic problem because of the low risk of
malignancy [2].
A  growing number of some promising immunohisto-
chemical (IHC) markers for the differential diagnosis of
thyroid  lesions have emerged, including CD56, Hector Bat-
tifora  mesothelial (HBME-1), galectin-3 (Gal-3) and CK19
but  till now none of them are conclusive [5,7].
CD56 is a neural cell adhesion molecule. Its expres-
sion may  affect the migratory capability of tumor cells.
Hence it is not surprising that loss of CD56 correlates
with metastatic potentials and poor prognostic outcome
in  some malignancies [7]. It has been reported to be
expressed in normal thyroid follicular cells with frequent
low  expression in malignant thyroid tumors especially
PTC [10].
HBME-1 is an antigen on the surface of mesothelial
cells. In thyroid neoplasms, Husain et al. [11] study showed
that  HBME-1 was positive in PTC and FC. However, none
of  them have shown a diagnostic accuracy sufﬁcient for
using  a single antibody in the diagnosis of malignant thy-
roid  neoplasms. Besides, no studies have been performed
to  determine whether HBME-1 is a useful diagnostic tool
for  distinguishing FA or Follicular Neoplasm/atypical cells
of  undetermined signiﬁcance (AUS) [12].
Galectin-3 is a component of the -galactoside bind-
ing lectins whose function is still unclear. It appears to
be  involved in the cell–cell and cell–matrix modulation.
Therefore, it could play a role in the malignant trans-
formation of thyroid cells and it is expressed in a high
proportion of carcinomas, especially of the papillary type
[11].  Recently, galectin-3 is initially shown to have utility
in  the differential diagnosis between benign and malignant
thyroid lesions [2]. But some recent studies suggest that it
is  not reliable [4,9,12].
Cytokeratin  19 (CK19) is a type I intermediate ﬁlament
protein and is widely present in simple epithelial cells [7].
Several  studies demonstrated strong and diffuse positivity
in  malignant thyroid tumors; however, it is not speciﬁc to
malignancy [3,11]. Several studies have shown conﬂicting
results regarding the usefulness of CK19 as a diagnostic
marker in thyroid lesions [7,13].
Most studies have evaluated the single expression of
markers in various thyroid lesions and a few reports
have studied the combined expression of markers [14,15].
Therefore, in this study, we evaluated the usefulness of
using  a panel of four markers (CD56, Gal-3, HBME-1, and
CK-19)  individually and in combination and their diagnos-
tic  value, in various follicular derived thyroid lesions. Our
aim  was to identify the diagnostic role of these markers in
the  follicular morphological mimics to determine their sen-
sitivity  and speciﬁcity in differential diagnosis of thyroid
nodules.WDTs-UMP (n = 7)
FT-UMP (n = 6)
2. Materials and methods
2.1.  Tissue specimens
Thyroid  gland lesions from January 2009 to January
2013 were searched through the database charts at the
pathology department of Tanta University Hospital. Demo-
graphic  information, gender, type of surgery, clinical data,
tumor  stage, treatment, tumor recurrence and follow up
were  reviewed. The study included 25 male and 45 female
patients with a median age of 32.5 years (range 13–78
years). The material of this retrospective study included
70  specimens of surgically removed, formalin-ﬁxed and
parafﬁn  embedded thyroid lesions. Furthermore, another
10  samples of randomly chosen normal thyroid tissue
obtained from radical laryngectomies for laryngeal car-
cinomas were included. This study was  approved by the
ethical  committee of the hospital. The tissue processing
and the general histological report were performed as
described previously by Ozolins et al. [16]. The diagnosis
and typing of thyroid pathology were performed according
to  the World Health Organization Classiﬁcation [17].
For  simplicity and practical clinical considerations,
the 70 selected thyroid lesions were divided into two
groups: benign (including nonneoplastic and neoplastic)
and malignant. The ﬁrst benign group (20 cases) included
4  Grave’s disease cases; 5 MNG  cases; 4 Hashimoto’s cases
and  7 FA cases, while the malignant group (50 cases) had
inclusion criteria as follows: differentiated thyroid cancer
originating from follicular epithelial cells except a Hürthle
cell  variant. This included 22 PTC cases; 15 FTC cases; 7
cases  of well differentiated tumors of unknown malignant
potential (WDTs-UMP) and 6 cases of follicular tumor of
unknown  malignant potential (FT-UMP). The 22 PTC cases
were  further classiﬁed into 14 cases of classic PTC and 8
cases  of FVPCs (Table 1).
For the diagnosis of FA, they were deﬁned as completely
encapsulated follicular tumors with homogeneous archi-
tecture  and morphology, without capsular and vascular
invasion [7]. While for PTC we  followed the histological
criteria proposed by Chan [18], which are divided into
major and minor features. The major features include: (1)
nuclei  are ovoid; (2) nuclei are crowded; (3) nuclei show
a  clear chromatin; and (4) psammoma  bodies are found.
If  one of the four features was lacking, four or more of
the  following features may  occur: (1) presence of abortive
papillae; (2) irregular shaped follicles; (3) dark colloid; (4)
copy and
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resence of nuclear pseudoinclusions; or (5) multinucle-
ted histiocytes in follicle lumen. Tumors were classiﬁed as
VPC  if they were composed completely or almost entirely
99%  of the tumor) of follicles lined by cells that had
he  nuclear features of PTC [8]. FC was diagnosed based
n  the presence of follicular proliferation with complete
apsule and full capsular penetration and/or vascular inva-
ion  [18]. WDT-UMP was represented by an encapsulated
umor composed of follicular cells having incompletely
eveloped papillary carcinoma-type nuclear changes. In
hese  tumors, there was no vessel invasion, while capsular
enetration was either absent or questionable. While FT-
MP  was deﬁned as an encapsulated tumor with follicular
rchitecture, having incomplete or questionable capsular
enetration, but neither vascular invasion nor papillary
arcinoma-type nuclear changes [19].
.2. Immunohistochemistry
All  80 samples (70 thyroid lesions and 10 normal thyroid
issues) were subjected to immunohistochemical stain-
ng  with CD56, HBME-1, Gal-3 and CK-19 antibodies. The
ections  were deparafﬁnized in xylene and rehydrated
hrough absolute alcohol. Antigen retrieval in citrate buffer
pH9  Lab vision cat#AP9003) was used after the sections
ere  treated in a microwave at 8 W for 5–6 min, then at
 W for 10 min, and the sections were then left to cool for
0  min. Peroxidase and protein blocks were done. After
hat  the slides were incubated overnight with the pri-
ary  antibodies at room temperature using CD56 antibody
clone  123C3; 1:100; Dako, Glostrup, Denmark); anti-
BME-1(clone HBME-1; 1:50; Dako, Glostrup, Denmark);
nti-Gal-3 monoclonal antibody NCL-Gal3, dilution 1:200
Novocastra, Newcastle, UK) and anti-CK-19 polyclonal
ntibody, dilution 1:100 (DakoCytomation) followed by
insing  in PBS (phosphate buffered saline, pH 7.6). This
as  followed by the secondary biotin conjugated antibody
or  1 h and ﬁnally the peroxidase conjugated streptavidin
or another hour. Diaminbenzidine tetrachloride (DAB) was
dded  for 25 min, and then counterstained in Hematoxylin,
ollowed by dehydration, clearing and mounting. The slides
f  positive and negative control were included in each run.
ositive  control for CD56 was neuroblastoma, mesothe-
ioma cells for HBME-1, histiocytes for galectin-3 and skin
or  CK19. Negative controls were done by excluding pri-
ary  antibody and its replacement with PBS [20].
.3. Interpretation of immunohistochemical staining of
he  studied markers
According to Park et al. [20], strong and complete mem-
ranous expression with or without cytoplasmic staining
f  the cells qualiﬁed the case as positive for CD56.
We  regarded cells as immunoreactive for HBME-1 when
he  signal was clearly observed in the cytoplasms and/or
he  membrane according to Yasuhiro et al. [4].
The cells were regarded as positive for Gal-3 when
mmunoreactivity was clearly observed in their nucleus
nd/or cytoplasm [9]. Ultrastructure 2 (2014) 127–136 129
A  positive membranous expression with or without
cytoplasmic staining in 10% or more of neoplastic cells
qualiﬁed the case as “positive (+)” for CK19 [11].
2.4. Scoring for the immunomarkers
A  semiquantitative assessment of immunohistochemi-
cal scoring was performed. For all antibodies, immunoreac-
tivity was considered positive if >10% of follicular epithelial
cells  stained [21]. The immunoreactivity was  scored as
negative, focally positive (+: less than 25%), positive (++:
25–50%)  or diffusely positive (+++: more than 50%), based
on  the extent of the reaction [4,6,20].
2.5. Statistical analysis
Data  were analyzed using the SPSS program Version
15. Comparison of qualitative variables between groups
was  done using the Chi-square or Fisher’s exact test. The
sensitivity and the speciﬁcity for each marker and their
combination in the diagnosis were calculated. Probability
values less than 0.05 were considered signiﬁcant [22].
3.  Results
3.1. Immunohistochemical expressions in normal thyroid
tissue
Strong CD56 positive expression was  found in the 10
samples of normal thyroid tissue 10/10 (100%). HBME-1
immunoreactivity was  not observed in normal follicu-
lar  epithelium, but was observed in scattered histiocytes.
Gal-3 expression was completely negative in the normal
thyroid tissue. Strong CK19 expression was observed in the
10  normal thyroid samples (100%).
3.2. Immunohistochemical expression in the studied
thyroid lesions (Table 2)
3.2.1.  1-CD56 expression in the studies lesions
Among the ﬁrst group, positive CD56 expression was
observed in 16/20 cases (80%), which included 3/4 cases of
Grave’s  disease (75%), 4/5 cases of MNG  (80%), 3/4 cases
of  Hashimoto’s thyroiditis (75%) and 6/7 cases of FA (86%)
[Fig.  1a]. All of the positive cases displayed strong CD56
expression (score +++). No statistical signiﬁcant difference
was  found among this group as regards CD56 expression
(P = 0.9).
Among the second group, positive CD56 expression was
observed in only 5/50 cases (10%), which included 2/14
classic PTC (14%, score ++). Fig. 2b shows example of the
negative PTC cases]. Besides, 1/8 cases of FVPC (13%, score
+)  [Fig. 1c], 2/15 cases of FC (13%, score +) [Fig. 1d], no
positive WDT-UMP nor FTs-UMP (0%). No statistical sig-
niﬁcant  difference was  found among this group as regards
CD56  expression (P = 0.5) but CD56 distinguished the sec-
ond  group from the ﬁrst group with a high statistically
signiﬁcant difference (P = 0.001).
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+) (a), PFig. 1. Immunohistochemical staining of CD56 in FA showing (++
3.2.2. 2-HBME-1 expression in the studied lesions
HBME-1 signal was detected predominantly in the cyto-
plasm.
Among  the ﬁrst group, positive HBME-1 expression was
observed in only 4/20 cases (20%), which included 1/4 cases
of  Grave’s disease (25%), 1/5 cases of MNG  (20%) [Fig. 2a
shows  example of the negative cases], besides 0/4 cases of
Hashimoto’s thyroiditis (0%) and 2/7 cases of FA (29%) were
positive.  All of the positive cases displayed week HBME-
1  expression (score +). No statistical signiﬁcant difference
was found among this group as regards HBME-1 expression
(P  = 0.08) but HBME-1 is higher in FA than other benign
lesions.
Among the second group, positive HBME-1 expression
was observed in 42/50 (84%), which included all the cases
of  PTC (100%, score +++) [Fig. 2b and c], 10/15 cases of FC
(67%,  score ++) [Fig. 2d], 6/7 cases of WDT-UMP (86%, score
++)  and 4/6 cases of FTs-UMP (67%, score ++) (0%). No statis-
tical  signiﬁcant difference was found among this group as
regards  HBME-1 expression (P = 0.06) but HBME-1 is higher
in  PTC than for other lesions in the second group. Besides,
between the ﬁrst and the second group, the difference was
highly  statistically signiﬁcant (P = 0.0004)3.2.3. 3-Galectin-3 expression in the studied lesions
Gal-3 expression was detected predominantly in the
cytoplasm and/or the nucleus.
Fig. 2. Immunohistochemical staining of HBME-1 in MNG (−) (a x100), PTCTC (−) (b), FVPC (+) (c) and FC (+) (d) [streptavidin biotin 200×].
Among the ﬁrst group, positive Gal-3 expression was
observed in only 4/20 cases (20%), in which 2/5 were cases
of  MNG  (40%, one case score+ and the other is score ++), and
2/7  were cases of FA (29%, score +) [Fig. 3a is an example of
the  negative FA cases]. All the remaining cases were nega-
tive.  No statistical difference was  found among this group
as  regards Gal-3 expression (P = 0.01).
Among  the second group; positive Gal-3 expression was
observed in 43/50 cases (86%), which included all the cases
of  classic PTC (100%, one case score+ one case score+ and 12
cases  score+++), all the cases of FVPC (100%, 2 cases score++
and  6 cases score+++) [Fig. 3b], 12/15 cases of FC (80%, one
cases  score+ 2 cases score++ and 9 cases score+++) [Fig. 3c],
5/7  cases of WDT-UMP (71%, one cases score+ one case
score++ and 3 cases score+++) and 4/6 cases of FTs-UMP
(67%, 2 cases score++ and 2 cases score+++) [Fig. 3d]. No sta-
tistical  difference was found among this group as regards
Gal-3 expression (P = 0.02) but Gal-3 is higher in PTC than
other  malignant lesions. Besides the relation between the
ﬁrst  and the second group was  highly statistically signiﬁ-
cant  (P = 0.005).
3.2.4. 4-CK19 expression in the studied lesions
CK19 expression was detected in the cell membranewith or without the cytoplasm.
Among the ﬁrst group, positive expression was
observed in only 7/20 cases (35%), which consisted of 1/4
cases  of Grave’s disease (25%, score +), 2/5 cases of MNG
 (+++) (b), FVPC (++) (c) and FC (++) (d) [streptavidin biotin 200×].
H.A. Alshenawy / Journal of Microscopy and Ultrastructure 2 (2014) 127–136 131
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Pig. 3. Immunohistochemical staining of galectin-3 in FA(−) (a x100), FV
40%, one case score+ and the other is score++) [Fig. 4a],
nd  4/7 cases of FA (57%, one is score+ three are score++).
ll the remaining cases were negative. No statistical signif-
cant  difference was found among the ﬁrst group as regards
K19  expression (P = 0.4)
Among the second group, positive CK19 expression was
bserved in 39/50 (87%), which included all the cases of
lassic  PTC (100%, one case score++, and 13 cases score+++)
Fig.  4b], all the cases of FVPC (100%, 5 cases score++ and
 cases score+++), 8/15 cases of FC (53%, 2 cases score+
Fig. 4c], 2 cases score++ and 4 cases score+++), 5/7 cases
f  WDT-UMP (71%, 2 cases score+ one case score++ and 2
ases  score+++) [Fig. 4d] and 4/6 cases of FTs-UMP (67%,
ne  cases score+ one case score++ and 2 cases score+++).
t  was statistically different among the second group as
egards  CK19 expression (P = 0.05). CK19 is always positive
n  PTC in contrast to the other malignant lesions. The rela-
ion  between the ﬁrst and the second group was highly
tatistically signiﬁcant (P = 0.003).
.3.  Speciﬁcity and sensitivity of each marker (Table 3)
Diagnostic validity of CD56 was of highest sensitivity in
ifferentiating FVPC from FA and in differentiating FC from
A  (86% in both), while the highest speciﬁcity was  in dif-
erentiating FC from FT-UMP (100%) and in differentiating
TC from benign non-neoplastic lesions (95%).
Fig. 4. Immunohistochemical staining of CK19 in MNG  (++) (a), PTC (+++) (b) (b x100), FC (+++) (c) and FT-UMP (+++) (d) [streptavidin biotin 200×].
For HBME-1, diagnostic sensitivity was  the greatest in
differentiating FVPC from FA (100%), FVPC from FC (100%),
PTC  from WDT-UMP (100%) and PTC from other benign
non-neoplastic lesions (100%), while the speciﬁcity was the
greatest  in differentiating benign from malignant lesions
(84%)  and PTC from other benign non-neoplastic lesions
(85%).
For  Gal-3, the highest sensitivity was observed during
differentiating FVPC from FA (100%), FVPC from FC (100%),
PTC  from WDT-UMP (100%) and PTC from benign non-
neoplastic lesions (100%), while the speciﬁcity was the
highest  in differentiating benign from malignant lesions
(80%)  and PTC from benign non-neoplastic lesions (85%).
In  CK19, the sensitivity was  maximum in differentiating
FVPC from FA (100%), FVPC from FC (100%), PTC from WDT-
UMP  (100%) and PTC from benign non-neoplastic lesions
(100%), while the speciﬁcity was the highest in differenti-
ating benign from malignant lesions (80%) and PTC from
benign  non-neoplastic lesions (85%).
3.4. Combined expression of markers and their
diagnostic value (Table 4)To improve the diagnostic accuracy of each marker,
we calculate the highest sensitivity and speciﬁcity for the
lesions  to analyze the combined effect of the markers.
, FC (+) (c) and WDT-UMP (+++) (d 400×) [streptavidin biotin 200×].
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Table 2
Immunohistochemical expression of the studied markers in different thyroid lesions.
Studied lesions CD56 P value HBME-1 P value Gal-3 P value CK19 P value
− + ++ +++ − + ++ +++ − + ++ +++ − + ++ +++
Normal thyroid tissue (10) 0 0 0 10 10 0 0 0 10 0 0 0 0 0 0 10
First group (20)
Grave’s  disease (4) 1 0 0 3 3 1 0 0 4 0 0 0 3 1 0 0
Multinodular goiter (5) 1 0 0 4 4 1 0 0 3 1 1 0 3 1 1 0
Hashimoto’s thyroiditis (4) 1 0 0 3 4 0 0 0 4 0 0 0 4 0 0 0
Thyroid adenoma (7) 1 0 0 6 5 2 0 0 5 2 0 0 3 1 3 0
P  value among the ﬁrst group 0.9 0.001 0.08 0.0004 0.01 0.005 0.4 0.003
Second group(50)
Papillary carcinoma
Classic  (14) 12 0 2 0 0 0 0 14 0 1 1 12 0 0 1 13
FVPC (8) 7 1 0 0 0 0 0 8 0 0 2 6 0 0 5 3
Follicular carcinoma (15) 13 2 0 0 5 0 10 0 3 1 2 9 7 2 2 4
WDT-UMP (7) 7 0 0 0 1 0 6 0 2 1 1 3 2 2 1 2
FT-UMP (6) 6 0 0 0 2 0 4 0 2 0 2 2 2 1 1 2
P  value among the second group 0.5 0.06 0.02 0.05
Table 3
Sensitivity and speciﬁcity of each marker in differential diagnosis of thyroid lesions.
Studied
marker
Benign  vs. malignant FVPC vs. FA FC vs. FA FVPC vs. FC FC vs. FT-UMP PTC vs. WDT-UMP PTC vs. benign
non-neoplastic
lesions
Sensitivity Speciﬁcity Sensitivity Speciﬁcity Sensitivity Speciﬁcity Sensitivity Speciﬁcity Sensitivity Speciﬁcity Sensitivity Speciﬁcity Sensitivity Speciﬁcity
CD56 80 90 86 88 86 87 13 87 13 100 14 14 77 95
HBME-1 80 84 100 71 67 71 100 33 67 33 100 14 100 85
Gal-3 80 80 100 71 80 71 100 20 80 33 100 29 100 85
CK19 65 78 100 43 53 43 100 47 53 33 100 29 100 77
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Table 4
Sensitivity and speciﬁcity of combined markers in differential diagnosis of thyroid lesions.
Studied marker Benign vs. malignant FVPC vs. FA FC vs. FA FVPC vs. FC FC vs. FT-UMP  PTC vs. WDT-UMP  PTC vs. benign
non-neoplastic
lesions
Sensitivity Speciﬁcity Sensitivity Speciﬁcity Sensitivity Speciﬁcity Sensitivity Speciﬁcity Sensitivity Speciﬁcity Sensitivity Speciﬁcity Sensitivity Speciﬁcity
CD56 and HMBE! 95 98 95 90 90 85 66 56 57 60 77 65 100 90
HBME-1 and
Galectin-3
85  87 100 100 85 80 100 40 80 45 100 40 100 100
CD56 and
Galectin-3
80  90 95 80 90 94 55 90 95 100 80 50 95 96
CD56 or CK19 70 82 100 55 80 60 100 90 50 70 75 30 100 85
CK19 or
Galectin-3
74  81 95 64 75 65 100 77 74 55 100 57 95 88
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To differentiate benign from malignant, we analyze the
speciﬁcity and sensitivity for CD56 or HBME-1, the sensi-
tivity  improved to 95% and the speciﬁcity improved to 98%.
For  FVPC vs. FA, we calculate the speciﬁcity and sensitiv-
ity  for HBME-1 or Galectin-3 or CD56, the sensitivity was
100%  and the speciﬁcity improved to 100%. To differentiate
FC  from FA, we calculate the speciﬁcity and sensitivity for
CD56  or Galectin-3, the sensitivity was 90% and the speci-
ﬁcity  improved to 94%, while to differentiate FVPC from
FC,  we calculate the speciﬁcity and sensitivity for CD56 or
CK19,  the sensitivity was 100% and the speciﬁcity improved
to  90%. To diagnose FC from FT-UMP, we analyze the speci-
ﬁcity  and sensitivity for CD56 or Galectin-3, the sensitivity
improved to 95% and the speciﬁcity improved to 100%. On
the  other hand, to differentiate PTC from WDT-UMP, we
examine  the speciﬁcity and sensitivity for CK19 or Galectin-
3,  the sensitivity was 100% and the speciﬁcity improved to
57%.  Lastly, to differentiate PTC from benign non-neoplastic
lesions, we check the speciﬁcity and sensitivity for HBME-1
or  Galectin-3, the sensitivity was 100% and the speciﬁcity
improved to 100%.
4.  Discussion
A  somewhat common dilemma is encountered with
tumors showing follicular growth pattern. Presence or
absence  of capsular and/or vascular invasion distinguishes
benign from malignant follicular tumors, but identiﬁcation
of  this ﬁnding can be challenging due to incomplete cap-
sular  penetration. Another situation is encountered when
some  of the nuclear features of PTC are present. Also in the
absence  of papillary architecture, distinguishing the FVPCs
from  cellular adenomatous nodules may  be challenging
[21].
For all of the aforementioned reasons, investigators
have focused during the last several years on ﬁnding IHC
markers  that can help in the distinction for these challeng-
ing  cases [5,23].
CD56  has been reported to be related to the differentia-
tion of the follicular epithelium and many previous studies
reported high CD56 expression in normal thyroid tissue
and  benign thyroid follicular lesions [10,24]. In accordance
with those studies, we currently report a high positive
CD56 expression in normal thyroid tissue and the benign
group. On the other hand, negative CD56 expression was
observed  in 90% of the second group cases. Similarly, pre-
vious  studies reported negative CD56 expression in all or
most  of their studied PTC cases [5,24].
Based on the previous results and in the light of our
ﬁnding, there was no statistically signiﬁcant difference
between CD56 expression among each group but CD56
distinguished the second group from the ﬁrst group so it
can  be used to differentiate FC from FA, FVPCs from other
benign nodules and PTC from benign lesions showing pap-
illary  structures. Therefore we were able to emphasize that
lack  of CD56 expression in FVPCs and PTC was very helpful
in  their discrimination from other follicular lesions. These
data  were in accordance with Arturs et al. [5].
The sensitivity and the speciﬁcity of CD56 as a nega-
tive marker were very impressive in distinguishing benign Ultrastructure 2 (2014) 127–136
lesions  from malignant lesions, FVPCs from FA, also in
differentiating FC from FA and in distinguishing PTC from
other  benign non-neoplastic lesions. On the other hand, the
highest  speciﬁcity was in differentiating FC from FT-UMP.
These results were in agreement with Dina et al. [7]. On
the  contrary, Etem et al. [25] found no statistical difference
between FVPCs and other follicular tumors (FTs-UMP, FA
and  FC) as regards CD56 expression.
HBME-1 has been reported to be one of the most
promising markers [14]. Among the benign group, positive
HBME-1 expression was weakly observed in 20%, 29% of
FA  were positive and it is higher in FA than other benign
lesions. This was differing from Arturs et al. [5] who found
no  HBME-1 in benign lesions.Among the malignant group,
positive  expression was observed in 84%, including all cases
of  PTC and 67% of FC. Miettinen et al. [26] showed that all
FC  were positive for HBME-1, although this phenomenon
could be observed in only 28% of FA. In Yasuhiro et al. [4]
and  Nasr et al. [21] study, there was  a signiﬁcant difference
in  the incidence of HBME-1 positivity between FC and FA.
In  the present study, HBME-1 expression is higher in PTC
than  other lesions in the second group, so it can be used to
differentiate FVPC from FC. Besides the difference between
the  ﬁrst and the second group was highly statistically sig-
niﬁcant  (P = 0.0004), so we can use it to differentiate PTC
from  other benign lesions and FA from FVPTC. These results
were  in agreement with Young et al. [12].
HBME-1 seems to be a sensitive marker for thyroid car-
cinoma, especially PTC. This was  in accordance with Prasad
et  al. [14] and Nasr et al. [21]. The sensitivity and the speci-
ﬁcity  for HBME-1 in distinguishing malignant from benign
were  80% and 84% respectively and this was in agreement
with Husain et al. [11] who showed that the sensitivity and
the  speciﬁcity of HBME-1 to distinguish benign from malig-
nant  lesions was  one of the highest among all markers.
Cheung et al. [27] reported HBME1 positivity in 70% classic
PTC  and 45% FVPC with no expression in nodular hyperpla-
sia  cases and FA. Similarly, Prasad et al. [14] demonstrated
HBME1 expression in 85% PTC.
In distinguishing FVPC from FA, the sensitivity and
the speciﬁcity were 100% and 71%, respectively while
in  differentiating PTC from other benign non-neoplastic
lesions, they were 100% and 85% respectively. On the other
hand,  HBME-1 showed highest sensitivity (100%) in distin-
guishing FVPC from FC and PTC from WDT-UMP, but the
speciﬁcity was  low. Husain et al. [22] study concluded that
HBME-1  is not a very good marker to distinguish adenomas
from thyroid carcinomas with over half of the adenomas
expressing this marker. Also Mauro et al. [6] in a study of
WDT-UMP found that a diffuse and strong expression of
HBME-1,  is observed. So, we  and others [1,6,22] can say
that  although HBME-1 contributes to the diagnosis of both
FC  and WDT-UMP, it cannot be applied alone in differen-
tial diagnosis of follicular-patterned lesions due to its low
speciﬁcity.
In  the present study, Gal-3 positive rate in two  groups
was  20% and 86%, respectively. Gasbarri et al. [28] observed
that  galectin-3 is never expressed in benign thyroid lesions.
Saggiorato et al. [29] observed only 4/52 FA expressing Gal-
3  immunopositivity, whereas all thyroid cancers that those
investigators analyzed were immunopositive for Gal-3. In
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he same way, Orlandi et al. [30] reported that although
ll the thyroid cancers that they analyzed were Gal-3
mmunopositive, only 3/29 FA exhibited such positivity.
ome authors consider true Gal-3-positive FA as an indi-
ation  of potentially early or incipient carcinoma, in which
he  capsular and/or vascular invasion cannot be histologi-
ally  observed as yet [31].
On  the other hand, some recent studies demonstrated
hat Gal-3 is highly expressed in benign thyroid lesions
nd  in normal thyroid tissue [12,14]. These discrepancies
ay  be related to the different antibody detection sys-
ems.  In the thyroid gland, endogenous biotin is invariably
xpressed in thyrocytes. Thus, a biotin-based detection
ystem may  provide false positive results. It has been
uggested that Gal-3 immunodetection may  be a useful
djunct in the distinction between benign and malignant
hyroid tumors, only if performed in a biotin-free detection
ystem [12].
In  the second group, all cases of PTC were positive, and
al-3  is higher in PTC than other malignant lesions, so we
an  use it to differentiate FVPC from FC; therefore Gal-3 has
een  consistently a very sensitive marker for PTC [14].In the
urrent  study, the relation between the ﬁrst and the sec-
nd  group was highly signiﬁcant and this was in agreement
ith Qingbin et al. [23], so it can be used to differentiate FC
rom  FA, FVPC from FA and PTC from other benign lesions.
In  a study by Bartolazzi et al. [32], the sensitivity and
he  speciﬁcity of Gal-3 in thyroid carcinomas were 99%
nd  98%, respectively. In Husain et al. [11] study the values
ere  92.6% and 77.3%, respectively. In the present study,
e  observed high sensitivity and speciﬁcity of Gal-3 in dif-
erentiating malignant from benign, FVPC from FA, FC from
A,  and PTC from other benign non-neoplastic lesions. Pre-
ious  studies revealed similar data and recommended its
se  to identify thyroid malignancies including FC and PTC
33,34].  On the other hand, the highest sensitivity for Gal-3
as  also observed in distinguishing FVPC from FC and PTC
rom  WDT-UMP (100% both) but the speciﬁcity was  low for
oth  (20% and 29% respectively).
Positive  CK19 expression was observed in 40% of MNG
nd  57% of FA. Some studies have reported negative CK19
taining in benign thyroid lesions [15], while Cheung et al.
27]  demonstrated that 20% of the nodular goiters were
ocally CK19 positive. In Debdas et al. [9] study, 50% of MNG
nd  75% of FA were positive but focal. The study by Nasr
t  al. [21] also noted a 68% CK19 positivity in benign lesions,
ut  staining intensity was  weak. Sahoo et al. [35] also found
K19  positivity in 100% of FA. In all these cases, CKI9 stain-
ng  was patchy and moderate. We  did not ﬁnd any strong
ositive FA. Nasr et al. [21] also demonstrated the weak
K19 status in 5/6 FAs. Guyetant et al. [36] showed that 90%
f  the FAs were focally positive for CK19. The signiﬁcance
f focal expression of CK19 in some FA is unknown. Further
tudies are necessary to show whether these tumors have
 different clinical behavior or molecular proﬁle.
On the other hand, among the second group, the pos-
tive  CK19 expression was observed for all the cases of
TC,  53% of FC, 71% of WDT-UMP and 67% of FTs-UMP.
ccording to Sahoo et al. [35] and Guyetant et al. [36] all
ases  of PTC showed strong positivity for CK19. The study
one  by Cheung et al. [27] observed that 57% of FVPC were Ultrastructure 2 (2014) 127–136 135
positive  for CK19, while Yoon et al. [3] study showed that
CK19  might be positive markers for the FVPC and they are
not  so useful for classic PC. In the current study, it was
observed that CK19 can differentiate FVPC from FC and
PTC  from both WDT-UMP and FTs-UMP, On the other hand
it  can differentiate PTC from benign lesions because the
difference between the ﬁrst and the second group was sta-
tistically  signiﬁcant.
The  sensitivity and the speciﬁcity as regards CK19 in
distinguishing malignant from benign were 65% and 78%
respectively but in distinguishing PTC from other benign
non-neoplastic lesions, the sensitivity and the speciﬁcity
were 100% and 77% respectively. The sensitivity was 100%
when  it was used to distinguish FVPC from FA, FVPC from FC
and  PTC from WDT-UMP but the speciﬁcity was low. Other
studies  showed a high sensitivity and speciﬁcity of CK19 in
PTC  [14,26]. They conﬁrmed that CK19 is a useful marker
for  differentiating PTC from papillary hyperplasia. How-
ever,  they also identiﬁed expression of CK19 in follicular
neoplasms and hence, in these studies and in our analyses
CK-19 alone was  not useful in the diagnosis of follicular
thyroid lesions. The chief utility of CK19 lies in its high
sensitivity for PTC. Negative staining for CK19, therefore,
is  strong evidence against PTC.
In summary, as no marker by itself has a superior
diagnostic value, a combination of markers may  be more
accurate than any single marker. We  attempted to iden-
tify  the best combination of markers with the greatest
speciﬁcity and sensitivity. CD56 with HBME-1 were the
best  to differentiate benign from malignant, CD56, HBME-
1  and Gal-3 were the best in differentiating FVPC from
FA,  while CD56 and Gal-3 were the best to distinguish FC
from  FA. CD56 was  the most speciﬁc in distinguishing FVPC
from  FC while the sensitivity was  the same as regards the
other  three markers. To distinguish FC from FT-UMP, the
best  were CD56 and Gal-3 while to differentiate PTC from
WDT-UMP, the best were Gal-3 and CK19. Lastly to dif-
ferentiate PTC from other benign non-neoplastic lesions,
the  best were HBME-1, Gal-3 and CD56. The sensitivity and
the  speciﬁcity were increased when we used combinations
of this panel together. Our recent observations encour-
aged us to assess the possible value of the (CD56, HBME-1,
Gaectin-3 and CK19) panel in the differential diagnosis of
the  studied thyroid nodules with a better sensitivity and
speciﬁcity. This panel was  able to discriminate benign from
malignant  lesions, PTC, FVPCs, FA, FC, FT-UMP and WDT-
UMP  among other similar follicular cell-derived thyroid
lesions.
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